# 2021 Radiopharmaceutical Therapy in Benign and Malignant Diseases:

Radiotheragnostic Practicum

## Release Date: February 15, 2021 | 10.25 AMA PRA Category 1 Credit(s)<sup>TM</sup>

#### About This CME Teaching Activity

This continuing education activity reviews best practices in the growing field of radiotheragnostics (aka theranostics or theragnostics) for benign and malignant diseases, beginning with the fundamentals and extending to include advanced clinical applications. A review of historically established therapies that have been optimally modernized as well as the recently introduced state-of-the-art modalities are included. The expert faculty discuss the optimization of the radiotheragnostic practices for best utilization of various radiopharmaceuticals in contemporary health care delivery systems, both academic and private practice settings.

#### **Target Audience**

This meeting is designed for nuclear medicine physicians, nuclear radiologists, oncologists, health physicists, and radiopharmacists.

#### **Scientific Sponsor**

Educational Symposia

#### Accreditation

**Physicians:** Educational Symposia is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Educational Symposia designates this enduring material for a maximum of 10.25 *AMA PRA Category 1 Credit(s)*<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All activity participants are required to take a written or online test in order to be awarded credit. (Exam materials, if ordered, will be sent with your order.) All course participants will also have the opportunity to critically evaluate the program as it relates to practice relevance and educational objectives.

> AMA PRA Category 1 Credit(s)™ for this activity may be claimed until February 14, 2024.

This program is planned and organized by Educational Symposia, a leader in accredited continuing education since 1975.

This activity was planned and produced in accordance with the ACCME Essential Areas and Elements.

#### **Educational Objectives**

At the completion of this CME teaching activity, you should be able to:

- The difference between the radiotheragnostic approach and various other concepts guiding the therapeutic delivery of radiation to the target tissues with the objective of improving health outcomes.
- The best therapeutic practice approaches to hyperthyroidism and other benign thyroid diseases, based on evidence and/or sound medical judgment.
- The best therapeutic practice approaches to differentiated thyroid carcinoma, based on evidence and/or sound medical judgment.
- The optimal applications of Y-90 Ibritumomab Tiuxetan for therapy of lymphoma.
- The optimal applications of I-131 Iobenguane to diagnostic imaging and therapy of Pheochromocytoma and Paraganglioma.
- The optimal applications of Y-90 Resin and Glass Microspheres to radioembolization therapy of liver cancers.
- The optimal applications of Ga-68 Dotatate Imaging and Lu-177 Dotatate therapy of neuroendocrine tumors.
- The optimal approach to diagnostic imaging of recurrent and metastatic prostate cancer.
- The best approach to therapy of skeletal metastatic disease using various Bone-Seeking radiopharmaceuticals.
- The practical examples for evaluation of not listed cancers for radiotheragnostics-based trials.
- Best approaches to building radiotheragnostic practice in academic institutions.
- Best approaches to building radiotheragnostic practice in private practice settings.
- No special educational preparation is required for this CME activity.

# Faculty

#### Samuel Mehr, M.D.

Diplomate, American Board of Nuclear Medicine Systemic Radiation Therapy and Theranostics Nebraska Cancer Specialists Omaha, NE

#### Erik S. Mittra, M.D., Ph.D.

Associate Professor, Diagnostic Radiology Division Chief, Nuclear Medicine & Molecular Imaging Oregon Health & Science University Portland, OR

### Program

#### Session 1

History & Practice of Radioiodine Therapy in Hyperthyroidism Mark Tulchinsky, M.D., FACNM, FSNMMI, CCD

Overview of Targeted Therapy - Lessons Learned *Terence Z. Wong, M.D., Ph.D.* 

Radioiodine Therapy: Uncommon Benign Thyroid Conditions Mark Tulchinsky, M.D., FACNM, FSNMMI, CCD

#### Session 2

I-131 lobenguane Imaging & Therapy for Pheochromocytoma/Paraganglioma *Erik S. Mittra M.D., Ph.D.* 

Radioiodine in Thyroid Cancer - Basics Mark Tulchinsky, M.D., FACNM, FSNMMI, CCD

#### Session 3

Radioiodine in Thyroid Cancer - Advanced Mark Tulchinsky, M.D., FACNM, FSNMMI, CCD

Radioembolization Therapy with Y-90 Resin and Glass Microspheres *Terence Z. Wong, M.D., Ph.D.* 

Ga-68/Lu-177 Dotatate Imaging/Therapy of Neuroendocrine Tumors *Erik S. Mittra M.D., Ph.D.* 

# Mark Tulchinsky, M.D., FACNM, FSNMMI, CCD

Professor of Radiology and Medicine Associate Director, Nuclear Medicine Penn State University Milton S. Hershey Medical Center Hershey, PA

#### Terence Z. Wong, M.D., Ph.D.

Professor of Radiology Chief, Division of Nuclear Medicine Director of Molecular and Translational Imaging University of North Carolina Chapel Hill Chapel Hill, NC

#### Session 4

Diagnostic Imaging of Recurrent and Metastatic Prostate Cancer Samuel Mehr, M.D.

Therapy for Skeletal Metastatic Disease with Bone-Seeking Agents *Terence Z. Wong, M.D., Ph.D.* 

Radiotheragnostics in Prostate Cancer *Terence Z. Wong, M.D., Ph.D.* 

#### Session 5

Pivotal Trials in the USA for Up-and-Coming Radiotheragnostics *Erik S. Mittra M.D., Ph.D.* 

Opportunities for Somatostatin Receptor Targeting in Avid Cancers *Samuel Mehr, M.D.* 

Building Nuclear Medicine Therapy Program in Academic Practice *Erik S. Mittra M.D., Ph.D.* 

Building Nuclear Medicine Therapy Program in Private Practice Samuel Mehr, M.D.

A CME Teaching Activity <b>2021 Radiopharmaceutical Therapy in Benign and Malignant Diseases:</b> Radiotheragnostic Practicum						ORDER ONLINE Or Call (813) 806-1000 To Purchase	
WATCHC	AMA PRA Category 1 Credit(s) <sup>™</sup> Available until February 14, 2024			□ ON-DE	MAND		
ORDER ONLINE and Search by Order ID at: ORDER ID				_		SUBTOTAL	
ENTIRE SET - 10.25 AMA PRA Category 1 Credit(s)™							
SYLLABUS: USE Purchase Full Colo	#	#	#				
SUBTOTAL							
For orders sent to a Florida address, please add 8.5% sales tax							
CME APPLICATION 1 application required per person				STREAM	ling	SUBTOTAL	
ENTIRE SET □ Online # at \$95 each □ Paper # at \$125 each				Included			
CME ADD PACKS	Includes Video Series, Syllabus & CME Application	n after initial purchase for additi	ional users.	STREAM		SUBTOTAL	
ENTIRE SET	CME Type: Online #	□ \$295	□ \$295	<b>\$195.00</b> Call (813) 80			
	□ Paper #			ToOrd			
SHIPPING	*Customer is solely responsible for the cost of duties,	customs, tariffs, import fees and	lor other costs a	ssociated with your	order	SUBTOTAL	
Domestic          □ Ground Shipping INCLUDED         □ Overnight (\$75)         □ 2nd Day (\$45)         □ 3rd Day (\$30)         □ \$175 (excluding Canada or Mexico)         □ \$75 Mexico & Canada         □         □         □							
GRAND TOTAL							
Name  M.D. D.O. Ph.D. P.A. Other							
ompany/Hospital Specialty							
Group Practice Name							
Address • No PO. Boxes. / We cannot be responsible for non-delivery when we receive an incorrect address. City / State / Zip / Country							
Phone	hone Email - For Shipment Notification & Online Test						
Card Number			Exp.	Date	Security Code		
Silling Address (If different than above) City / State / Zip / Country							
Cardholder Signature							
-	ys To Order We Accept		8				
	TERNET	MAIL	FAX		PHONE		
	USB or DVD: www.edusymp.com	Check payable to: Educational Symposia	(813) 806-	1001	(813) 806-1000		
	Demand 1 11	5620 West Sligh Avenue Tampa, Florida 33634-4490					

USB & DVD Cancellation Policy: Cancellations must be received in writing. Returns will be accepted within 15 days of receiving the product. No refunds will be issued after 15 days. There will be a \$125.00 processing fee as well as shipping changes applied to all refunds. No credit can be applied on returned purchases. 2+ returns voids cancellation policy.

**On-Demand Cancellation Policy:** We offer a free trial period. Please use the evaluation period to ensure your online system meets the requirements necessary to view. If you are not satisfied, you may receive a refund within 90 days if you have watched less than 20% of your purchase.